Lu CY, Chiang CS, Chiu CH, Wang ET, Chen YY, Yao SM, et al. Successful control of Streptococcus pneumoniae 19A replacement with a catch-up primary vaccination program in Taiwan. Clin Infect Dis. 2019;69:1581–7. https://doi.org/10.1093/cid/ciy1127.
Chen CH, Janapatla RP, Su LH, Li HC, Kuo KC, Chien CC, Hsiao CC, Chiu CH. Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: a multi-center clinical microbiological study after PCV13 implementation. J Infect. 2022;84(6):788–94. https://doi.org/10.1016/j.jinf.2022.04.022.
Article PubMed CAS Google Scholar
Janapatla RP, Hsu MH, Chen CL, Wei SH, Yu MJ, Su LH, et al. Persistence of immunity in children immunised with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage: a cross-sectional study. Thorax. 2020;75:689–92. https://doi.org/10.1136/thoraxjnl-2019-213878.
Chen CH, Chen CL, Arguedas A, Southern J, Hsiao CC, Chiu CH. Divergent serotype distribution between children with otitis media and those without in the pneumococcal conjugate vaccine era. J Microbiol Immunol Infect. 2020;53:1035–8. https://doi.org/10.1016/j.jmii.2020.05.003.
Article PubMed CAS Google Scholar
Chapman TJ, Pichichero ME, Kaur R. Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine. Hum Vaccin Immunother. 2020;16:3201–7. https://doi.org/10.1080/21645515.2020.1753438.
Article PubMed PubMed Central CAS Google Scholar
Farmaki PF, Chini MC, Mangafas NM, Tzanoudaki MT, Piperi CP, Lazanas MZ, et al. Immunogenicity and immunological memory induced by the 13-valent pneumococcal conjugate followed by the 23-valent polysaccharide vaccine in HIV-infected adults. J Infect Dis. 2018;218:26–34. https://doi.org/10.1093/infdis/jiy135.
Article PubMed CAS Google Scholar
Papadatou I, Tzovara I, Licciardi PV. The role of serotype-specific immunological memory in pneumococcal vaccination: current knowledge and future prospects. Vaccines (Basel). 2019;7:13. https://doi.org/10.3390/vaccines7010013.
Article PubMed CAS Google Scholar
Pennington SH, Pojar S, Mitsi E, Gritzfeld JF, Nikolaou E, Solórzano C, et al. Polysaccharide-specific memory B cells predict protection against experimental human pneumococcal carriage. Am J Respir Crit Care Med. 2016;194:1523–31. https://doi.org/10.1164/rccm.201512-2467oc.
Article PubMed PubMed Central CAS Google Scholar
Swarthout TD, Henrion MYR, Thindwa D, Meiring JE, Mbewe Maurice KO, Akuzike, et al. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study. Lancet Infect Dis. 2022;22:1737–47. https://doi.org/10.1016/s1473-3099(22)00438-8.
Oligbu G, Hsia Y, Folgori L, Collins S, Ladhani S. Pneumococcal conjugate vaccine failure in children: a systematic review of the literature. Vaccine. 2016;34:6126–32. https://doi.org/10.1016/j.vaccine.2016.10.050.
Article PubMed CAS Google Scholar
Pneumococcal vaccination. Summary of who and when to vaccinate. Available at https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html. [Accessed November 11, 2023].
Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514–9. https://doi.org/10.1128/cdli.10.4.514-519.2003.
Article PubMed PubMed Central CAS Google Scholar
Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006–2018. Vaccine. 2019;37:4491–8. https://doi.org/10.1016/j.vaccine.2019.06.071.
Adebanjo TA, Pondo T, Yankey D, Hill HA, Gierke R, Apostol M, et al. Pneumococcal conjugate vaccine breakthrough infections: 2001–2016. Pediatrics. 2020;145:e20190836. https://doi.org/10.1542/peds.2019-0836.
Bertran M, D’Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis 2024 Feb 1:S1473–3099(23)00706–5. https://doi.org/10.1016/S1473-3099(23)00706-5
Silva-Costa C, Gomes-Silva J, Pinho MD, Friães A, Ramirez M, Melo-Cristino J. Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019). Microbiol Spectr. 2022;10:e0107722. https://doi.org/10.1128/spectrum.01077-22.
Article PubMed CAS Google Scholar
Ricketson LJ, Bettinger JA, Sadarangani M, Halperin SA, Kellner JD. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: an IMPACT study. Vaccine. 2022;40:2733–40. https://doi.org/10.1016/j.vaccine.2022.03.048.
Article PubMed CAS Google Scholar
Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022;21:201–14. https://doi.org/10.1080/14760584.2022.2012455.
Article PubMed CAS Google Scholar
Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14:839–46. https://doi.org/10.1016/s1473-3099(14)70822-9.
Article PubMed CAS Google Scholar
Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816–26. https://doi.org/10.1016/j.vaccine.2007.01.119.
Article PubMed CAS Google Scholar
Lee HY, Hsieh YC, Liu CC, Huang YC, Chang KY, Chi H, et al. Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules. J Microbiol Immunol Infect. 2018;51:199–206. https://doi.org/10.1016/j.jmii.2017.08.022.
Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. Vaccine. 2015;33:1719–25. https://doi.org/10.1016/j.vaccine.2015.02.005.
Article PubMed CAS Google Scholar
Trück J, Thompson A, Morales-Aza B, Clutterbuck EA, Voysey M, Clarke E, et al. Memory B cell response to a PCV-13 booster in 3.5 year old children primed with either PCV-7 or PCV-13. Vaccine. 2017;35:2701–8. https://doi.org/10.1016/j.vaccine.2017.03.079.
Article PubMed CAS Google Scholar
Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149–59. https://doi.org/10.1038/nri3802.
Article PubMed CAS Google Scholar
Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK. Different B cell populations mediate early and late memory during an endogenous immune response. Science. 2011;331:1203–7. https://doi.org/10.1126/science.1201730.
Article PubMed PubMed Central CAS Google Scholar
Micoli F, Romano MR, Carboni F, Adamo R, Berti F. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj J. 2023;40:135–48. https://doi.org/10.1007/s10719-023-10100-3.
Article PubMed PubMed Central CAS Google Scholar
Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952–62. https://doi.org/10.1093/cid/cit428.
留言 (0)